The dual action of ONT-380, which is an oral, HER2-selective, central nervous system (CNS)-active tyrosine kinase inhibitor, may be able to help women combat advanced HER2-positive breast cancer.
HER2-Positive Breast Cancer
T-DM1 improved survival in women with HER2-positive breast cancer, even after treatment with two or more other HER2-targeted therapies including trastuzumab and lapatinib.
Dual HER2 blockade with trastuzumab and lapatinib was no better than trastuzumab alone in producing pathologic complete responses in metastatic HER2-positive breast cancer patients in the neoadjuvant setting, according to a new study.
Neratinib Improves Invasive Disease-Free Survival in Centrally Confirmed HER2-Positive Breast Cancer
Neratinib significantly improves invasive disease-free survival (iDFS) in trastuzumab (Herceptin)-treated, early-stage, human epidermal growth factor receptor 2-positive (HER2+) breast cancer patients, with an enhanced treatment effect observed in women with centrally confirmed HER2+ tumors.
Adding pertuzumab to first-line therapy for HER2-positive breast cancer has been shown to yield a survival benefit, but a new analysis says adding the drug is not cost effective.
Breast cancer patients with PIK3CA gene mutations may not benefit from dual anti-HER2 inhibition, according to a new study in The Oncologist.
Neoadjuvant TDM-1 was shown to be effective in treating HER2-positive, HR-positive breast cancer compared with trastuzumab, with or without endocrine therapy.
The addition of pertuzumab to trastuzumab and docetaxel offers significant improvement over other options in patients with HER2-positive breast cancer.
A randomized trial failed to show non-inferiority of 6 months of adjuvant trastuzumab compared with the standard 12 months for HER2-positive breast cancer.
MM-302 showed encouraging efficacy results and a manageable safety profile in heavily pretreated HER2-positive metastatic breast cancer patients.